<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncol Res Treat</journal-id><journal-id journal-id-type="iso-abbrev">Oncol Res Treat</journal-id><journal-id journal-id-type="publisher-id">ORT</journal-id><journal-title-group><journal-title>Oncology Research and Treatment</journal-title></journal-title-group><issn pub-type="ppub">2296-5270</issn><issn pub-type="epub">2296-5262</issn><publisher><publisher-name>S. Karger GmbH</publisher-name><publisher-loc>Wilhelmstrasse 20A, P.O. Box &#x000b7; Postfach &#x000b7; Case postale, D&#x02013;79095, Freiburg, Germany &#x000b7; Deutschland &#x000b7; Allemagne, Phone: +49 761 45 20 70, Fax: +49 761 4 52 07 14, information@karger.de</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7270058</article-id><article-id pub-id-type="doi">10.1159/000508452</article-id><article-id pub-id-type="publisher-id">ort-0001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Community-Acquired Respiratory Viruses in Oncology: Lessons to Be Learnt from the SARS-CoV-2 Pandemic</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>von Lilienfeld-Toal</surname><given-names>Marie</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label><sup>a</sup>Abteilung f&#x000fc;r H&#x000e4;matologie und internistische Onkologie, Klinik f&#x000fc;r Innere Medizin II, Universit&#x000e4;tsklinikum Jena, Jena, Germany</aff><aff id="aff2"><label>2</label><sup>b</sup>Leibniz-Institut f&#x000fc;r Infektionsbiologie und Naturstoff Forschung, Hans-Kn&#x000f6;ll Institut, Jena, Germany</aff><author-notes><corresp id="cor1">*Marie von Lilienfeld-Toal, Abteilung f&#x000fc;r H&#x000e4;matologie und internistische Onkologie, Klinik f&#x000fc;r Innere Medizin II, Universit&#x000e4;tsklinikum Jena, Am Klinikum 1, DE&#x02013;07747 Jena (Germany), <email>Marie.von_Lilienfeld-Toal@med.uni-jena.de</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>14</day><month>5</month><year>2020</year></pub-date><volume>43</volume><issue>6</issue><fpage>262</fpage><lpage>263</lpage><history><date date-type="received"><day>4</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>5</day><month>5</month><year>2020</year></date><date date-type="subscription-year"><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 by S. Karger AG, Basel</copyright-statement><copyright-year>2020</copyright-year><license license-type="free" xlink:href="https://www.karger.com/Services/SiteLicenses"><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><counts><ref-count count="9"/><page-count count="2"/></counts></article-meta></front><body><p>As a hematologist with an interest in infectious diseases I would like to use this opportunity to repeat a long-standing message: community-acquired respiratory viruses (CARV) are potential killers, especially for cancer patients [<xref rid="B1" ref-type="bibr">1</xref>]. Influenza has long been famous for causing seasonal excess mortality in all populations and is therefore well known as a dangerous pathogen in cancer patients in particular [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>]. Other CARV with complicated names such as respiratory syncytial virus (RSV), parainfluenza, or human metapneumovirus (hMPV) have also been described as causes of pneumonia with high fatality rates in patients with hematological malignancies inside and outside the transplant setting [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>]. It seems that shortly after the novel description of a respiratory virus oncologists have previously never heard of, there is the report of an outbreak, sometimes with fatal consequences, on a hematology/oncology unit somewhere on the globe [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. So why should this be any different for SARS-CoV-2? The characteristics are the same, albeit probably aggravated, as for the other CARV: firstly, an infection with SARS-CoV-2 is per se potentially dangerous, secondly, the virus is highly contagious and has a high potential for nosocomial transmission, and lastly, clinicians are not used to and thus not sufficiently aware of this particular pathogen.</p><p>In this issue of <italic>Oncology Research and Treatment</italic>, there is the report of an outbreak of SARS-CoV-2 on a hematology unit together with the description of its successful containment along with a review of a possible strategy to manage care for cancer patients in times of COVID-19. There are several lessons to be learnt from this valuable report:</p><p>Outbreaks with CARV happen, and they happen to anyone, even to units of the highest standards.</p><p>Outbreaks with CARV need to be recognized quickly, and effective measures need to be taken rapidly, although they may appear radical at times.</p><p>If dealt with appropriately, outbreaks can be contained, and cancer care can be ensured at the highest possible standard even in times of a pandemic.</p><p>The most important resource to continue cancer care in the situation of a pandemic is enough dedicated staff.</p><p>So, what does it take to make sure all cancer patients receive optimal therapy during the COVID-19 crisis? We need to take the virus and the disease it causes absolutely seriously. We need to find the right balance between implementing appropriate precautions on the one hand and causing collateral damage by denying cancer patients the tumor therapy they need on the other hand. Recommendations should be as rational and evidence-based as possible (as they usually are in cancer care). For this, high-quality evidence needs to be gathered as quickly as possible, and the development of recommendations even in times of crisis should be consensus-based with critical appraisal. The aim is to care for our patients as safely and as effectively as we usually do, which has led to the well-described increase in survival and quality of life in the recent years [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>].</p><p>In my impression, this is exactly what the community of hematologists and oncologists has been striving for with an immense effort over the past weeks. All clinicians and healthcare workers involved in either treating COVID-19 patients or working hard to compensate potential implications on routine cancer care cannot be thanked enough.</p><p>If the efforts of everyone involved are recognized and the lessons learnt from the SARS-CoV-2 pandemic kept in mind, the community is well prepared for any other upcoming crisis, including safe management of the yearly mini-crisis of seasonal CARV epidemics.</p><sec sec-type="COI-statement" id="sec1_1"><title>Disclosure Statement</title><p>Honoraria/consulting fees: Celgene, Janssen, Takeda, Amgen, Oncopeptides, Cancer Drug Development Forum, Gilead, Merck, and BMS. Research funding: Celgene, Gilead, Novartis, and Deutsche Krebshilfe.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Lilienfeld-Toal</surname><given-names>M</given-names></name><name><surname>Maschmeyer</surname><given-names>G</given-names></name></person-group><article-title>Challenges in Infectious Diseases for Haematologists</article-title><source>Oncol Res Treat</source><year>2018</year><volume>41</volume><issue>(6)</issue><fpage>406</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">29734194</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ljungman</surname><given-names>P</given-names></name><name><surname>de la Camara</surname><given-names>R</given-names></name><name><surname>Perez-Bercoff</surname><given-names>L</given-names></name><name><surname>Abecasis</surname><given-names>M</given-names></name><name><surname>Nieto Campuzano</surname><given-names>JB</given-names></name><name><surname>Cannata-Ortiz</surname><given-names>MJ</given-names></name><etal/><collab>Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation</collab><collab>Infectious Complications Subcommittee, Spanish Group of Haematopoietic Stem-cell Transplantation</collab></person-group><article-title>Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients</article-title><source>Haematologica</source><year>2011</year><month>8</month><volume>96</volume><issue>(8)</issue><fpage>1231</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">21546495</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chemaly</surname><given-names>RF</given-names></name><name><surname>Vigil</surname><given-names>KJ</given-names></name><name><surname>Saad</surname><given-names>M</given-names></name><name><surname>Vilar-Compte</surname><given-names>D</given-names></name><name><surname>Cornejo-Juarez</surname><given-names>P</given-names></name><name><surname>Perez-Jimenez</surname><given-names>C</given-names></name><etal/></person-group><article-title>A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes</article-title><source>Cancer</source><year>2012</year><month>9</month><volume>118</volume><issue>(18)</issue><fpage>4627</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">22359314</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sydnor</surname><given-names>ER</given-names></name><name><surname>Greer</surname><given-names>A</given-names></name><name><surname>Budd</surname><given-names>AP</given-names></name><name><surname>Pehar</surname><given-names>M</given-names></name><name><surname>Munshaw</surname><given-names>S</given-names></name><name><surname>Neofytos</surname><given-names>D</given-names></name><etal/></person-group><article-title>An outbreak of human parainfluenza virus 3 infection in an outpatient hematopoietic stem cell transplantation clinic</article-title><source>Am J Infect Control</source><year>2012</year><month>9</month><volume>40</volume><issue>(7)</issue><fpage>601</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">22405748</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehners</surname><given-names>N</given-names></name><name><surname>Schnitzler</surname><given-names>P</given-names></name><name><surname>Geis</surname><given-names>S</given-names></name><name><surname>Puthenparambil</surname><given-names>J</given-names></name><name><surname>Benz</surname><given-names>MA</given-names></name><name><surname>Alber</surname><given-names>B</given-names></name><etal/></person-group><article-title>Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit</article-title><source>Bone Marrow Transplant</source><year>2013</year><month>11</month><volume>48</volume><issue>(12)</issue><fpage>1548</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">23811816</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spahr</surname><given-names>Y</given-names></name><name><surname>Tschudin-Sutter</surname><given-names>S</given-names></name><name><surname>Baettig</surname><given-names>V</given-names></name><name><surname>Compagno</surname><given-names>F</given-names></name><name><surname>Tamm</surname><given-names>M</given-names></name><name><surname>Halter</surname><given-names>J</given-names></name><etal/></person-group><article-title>Community-Acquired Respiratory Paramyxovirus Infection After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience</article-title><source>Open Forum Infect Dis</source><year>2018</year><month>4</month><volume>5</volume><issue>(5)</issue><fpage>ofy077</fpage><pub-id pub-id-type="pmid">29780847</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Im</surname><given-names>HJ</given-names></name><name><surname>Hong</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>MN</given-names></name></person-group><article-title>Molecular epidemiological investigation of a nosocomial outbreak of human metapneumovirus infection in a pediatric hemato-oncology patient population</article-title><source>J Clin Microbiol</source><year>2009</year><month>4</month><volume>47</volume><issue>(4)</issue><fpage>1221</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">19213698</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>M</given-names></name><name><surname>Rutherford</surname><given-names>MJ</given-names></name><name><surname>Bardot</surname><given-names>A</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>TM</given-names></name><name><surname>Myklebust</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study</article-title><source>Lancet Oncol</source><year>2019</year><month>11</month><volume>20</volume><issue>(11)</issue><fpage>1493</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">31521509</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carioli</surname><given-names>G</given-names></name><name><surname>Bertuccio</surname><given-names>P</given-names></name><name><surname>Boffetta</surname><given-names>P</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>La Vecchia</surname><given-names>C</given-names></name><name><surname>Negri</surname><given-names>E</given-names></name><etal/></person-group><article-title>European cancer mortality predictions for the year 2020 with a focus on prostate cancer</article-title><source>Ann Oncol</source><year>2020</year><month>5</month><volume>31</volume><issue>(5)</issue><fpage>650</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">32321669</pub-id></element-citation></ref></ref-list></back></article>